NCT03960268View on ClinicalTrials.gov

Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

May 28, 2019

Primary Completion Date

June 1, 2020

Study Completion Date

June 1, 2020

Conditions

Hidradenitis Suppurativa

Interventions

DRUG

Brodalumab

interleukin 17 receptor A antagonist

Trial Locations (1)

10065

Rockefeller Unviersity, New York

Sponsors

Collaborators (1)

Valeant Pharmaceuticals

All Listed Sponsors

collaborator

Valeant Pharmaceuticals

INDUSTRY

lead

Rockefeller University

OTHER

NCT03960268 - Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab | Biotech Hunter | Biotech Hunter